J
Johnson Paul D
Researcher at Pfizer
Publications - 36
Citations - 1304
Johnson Paul D is an academic researcher from Pfizer. The author has contributed to research in topics: HIV Protease Inhibitor & Sulfonamide. The author has an hindex of 18, co-authored 36 publications receiving 1265 citations. Previous affiliations of Johnson Paul D include Brown University & General Electric.
Papers
More filters
Journal ArticleDOI
Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇
Steve Turner,Strohbach Joseph Walter,Tommasi Ruben A,Paul A. Aristoff,Johnson Paul D,Harvey Irving Skulnick,Lester A. Dolak,Eric P. Seest,Paul K. Tomich,Michael John Bohanon,M.‐M. Horng,J. C. Lynn,Chong Kt,R. R. Hinshaw,K. D. Watenpaugh,M.N. Janakiraman,Suvit Thaisrivongs +16 more
TL;DR: Crystallographic studies provided further information on important binding interactions responsible for high enzymatic binding and led to compound VI, which inhibits HIV protease with a Ki value of 8 pM and shows an IC90 value of 100 nM in antiviral cell culture.
Journal ArticleDOI
Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Donna L. Romero,Raymond A. Morge,Carolyn Biles,Norman Berrios-Pena,Paul D. May,John R. Palmer,Johnson Paul D,Herman W. Smith,Mariano Busso +8 more
TL;DR: Replacement of the substituted aryl moiety with various substituted indoles provided bis(heteroaryl)piperazines (BHAPs) that were 10-100-fold more potent than U-80493E.
Journal ArticleDOI
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.
Suvit Thaisrivongs,Harvey Irving Skulnick,Steve Turner,Strohbach Joseph Walter,Tommasi Ruben A,Johnson Paul D,Paul A. Aristoff,T M Judge,Ronald B. Gammill,Joel Morris,Karen Rene Romines,R. A. Chrusciel,R. R. Hinshaw,Chong Kt,W G Tarpley,S M Poppe,D E Slade,J. C. Lynn,M.‐M. Horng,Tomich Pk,Eric P. Seest,Lester A. Dolak,Howe Wj,G.M Howard,K. D. Watenpaugh +24 more
Journal ArticleDOI
Structure-Based Design of HIV Protease Inhibitors: 5,6-Dihydro-4-hydroxy-2-pyrones as Effective, Nonpeptidic Inhibitors
Suvit Thaisrivongs,Donna L. Romero,Tommasi Ruben A,M.N. Janakiraman,Strohbach Joseph Walter,Turner,Carolyn Biles,Morge Rr,Johnson Paul D,Paul A. Aristoff,Tomich Pk,J. C. Lynn,M.‐M. Horng,Chong Kt,R. R. Hinshaw,Howe Wj,Barry C. Finzel,K. D. Watenpaugh +17 more
TL;DR: From this study, compound XIX exhibited reasonably high enzyme inhibitory activity and showed antiviral activity in the cell-culture assay and provided a research direction which led to the discovery of active 5,6-dihydro-4-hydroxy-2-pyrones as potential agents for the treatment of HIV infection.
Journal ArticleDOI
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
Harvey Irving Skulnick,Johnson Paul D,Paul A. Aristoff,Joel Morris,K D Lovasz,Howe Wj,K. D. Watenpaugh,M.N. Janakiraman,David J. Anderson,R J Reischer,Theresa M. Schwartz,L. S. Banitt,Tomich Pk,J. C. Lynn,M.‐M. Horng,Chong Kt,R. R. Hinshaw,Lester A. Dolak,Eric P. Seest,F.J Schwende,Bob D. Rush,G.M Howard,L. N. Toth,K.R Wilkinson,Thomas J. Kakuk,C.W Johnson,Serena L. Cole,Renee M. Zaya,G.L Zipp,P.L Possert,R.J Dalga,W.-Z Zhong,M. G. Williams,Karen Rene Romines +33 more
TL;DR: The p-cyanophenyl sulfonamide derivative 35k emerged as a promising inhibitor, was selected for further development, and entered phase I clinical trials.